Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

Must have received: systemic chemotherapy — first-line

Patients undergoing first-line systemic chemotherapy progression or intolerance (progress in maintenance therapy after first-line chemotherapy can also be included). Synchronous chemoradiotherapy for postoperative recurrence or metastasis is considered as first-line treatment; For radical concurrent chemoradiotherapy, neoadjuvant/adjuvant therapy (chemotherapy or chemoradiotherapy), if disease progression occurs during treatment or within 6 months after stopping treatment, Count it as a first-line treatment failure.

Cannot have received: radiotherapy, chemotherapy, hormonal therapy, surgery, or molecular-targeted therapy

Exception: eligible if last dose of anti-neoplastic medication was discontinued for ≥5 half-lives before the initial treatment

Prior radiotherapy, chemotherapy, hormonal therapy, surgery, or molecular-targeted therapy within 4 weeks of enrollment (eligible for enrollment if the last dose of anti-neoplastic medication was discontinued for ≥5 half-lives before the initial treatment); prior chemotherapy with nitrosoureas or mitomycin within 6 weeks of enrollment.

Cannot have received: chemotherapy with nitrosoureas or mitomycin

prior chemotherapy with nitrosoureas or mitomycin within 6 weeks of enrollment

Cannot have received: concurrent anti-neoplastic treatments

Concurrent administration of other anti-neoplastic treatments